Skip to main content

As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.

2021 Thematic Series: mRNA therapies and mRNA vaccines in cancer

2021 SI imageMolecular Cancer is delighted to announce the new thematic series entitled 'mRNA therapies and mRNA vaccines in cancer.'

Click here to view this collection.

Click here to access all thematic series published to date in Molecular Cancer.

Editor-in-Chief

Christophe Nicot, Kansas University Medical Center, USA

Aims and scope

Molecular Cancer is an open access, peer-reviewed journal interested in attracting high-quality original research and reviews that present or highlight significant advances in all areas of cancer and related biomedical science.

Read more

Articles

Featured Article: Role of the NLRP3 inflammasome in cancer

In this review, Sahebkar et al. summarize the current knowledge on the contribution of the NLRP3 inflammasome on potential cancer promotion and therapy.


Recognising Editorial Excellence

Editorial Excellence BadgeMolecular Cancer is a top rated Springer Nature journal. Prof. Christophe Nicot and the editorial team performed in the top percentile of journals based on data collected from the Journal Author Satisfaction Survey. We are recognising extraordinary editors for their commitment and passion to their journals. Read more about editorial excellence here.

What is trending?

Altmetric doughnutClick here to see which articles published in Molecular Cancer have been shared the most in the past three months.

Annual Journal Metrics

\